home / stock / ziop / ziop quote
Last: | $0.8657 |
---|---|
Change Percent: | -0.88% |
Open: | $0.91 |
Close: | $0.8657 |
High: | $0.97 |
Low: | $0.8611 |
Volume: | 2,127,346 |
Last Trade Date Time: | 01/26/2022 04:56:14 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.8657 | $0.91 | $0.8657 | $0.97 | $0.8611 | 2,127,346 | 01-26-2022 |
$0.8734 | $0.9314 | $0.8734 | $0.9314 | $0.8401 | 1,723,613 | 01-25-2022 |
$0.9191 | $0.8006 | $0.9191 | $0.9399 | $0.7703 | 2,186,311 | 01-24-2022 |
$0.817 | $0.8523 | $0.817 | $0.8846 | $0.817 | 1,882,458 | 01-21-2022 |
$0.861 | $0.93 | $0.861 | $0.96 | $0.86 | 1,816,743 | 01-20-2022 |
$0.8961 | $0.87 | $0.8961 | $0.95 | $0.87 | 1,858,546 | 01-19-2022 |
$0.8553 | $0.89 | $0.8553 | $0.9288 | $0.8553 | 2,672,931 | 01-18-2022 |
$0.946 | $0.91 | $0.946 | $0.96 | $0.851 | 2,430,695 | 01-17-2022 |
$0.946 | $0.91 | $0.946 | $0.96 | $0.851 | 2,413,273 | 01-14-2022 |
$0.883 | $0.96 | $0.883 | $0.9897 | $0.883 | 1,563,289 | 01-13-2022 |
$0.9449 | $1 | $0.9449 | $1.01 | $0.9401 | 1,866,682 | 01-12-2022 |
$1 | $0.99 | $1 | $1.065 | $0.9801 | 1,215,606 | 01-11-2022 |
$0.9857 | $1 | $0.9857 | $1.005 | $0.932 | 1,570,322 | 01-10-2022 |
$0.9955 | $1 | $0.9955 | $1.05 | $0.9901 | 1,022,067 | 01-07-2022 |
$1.02 | $1.02 | $1.02 | $1.055 | $0.9877 | 2,242,379 | 01-06-2022 |
$1.01 | $1.1 | $1.01 | $1.135 | $1.01 | 2,997,932 | 01-05-2022 |
$1.09 | $1.17 | $1.09 | $1.18 | $1.09 | 2,636,352 | 01-04-2022 |
$1.17 | $1.09 | $1.17 | $1.18 | $1.085 | 1,888,218 | 01-03-2022 |
$1.09 | $1.15 | $1.09 | $1.17 | $1.09 | 2,204,719 | 12-31-2021 |
$1.12 | $1.1 | $1.12 | $1.21 | $1.0704 | 2,629,438 | 12-30-2021 |
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...